Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Invobenitug (Procizumab/PCZ/AK1967) in cardiogenic shock
NL-OMON59337Phase 2Recruiting
- Sponsor
- 4TEEN4 Pharmaceuticals
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of invobenitug in cardiogenic shock, acute coronary syndrome (ACS), sepsis and 1 more, sponsored by 4TEEN4 Pharmaceuticals. Started Jul 2025; status: recruiting.
02
Drugs
invobenitug
03
Conditions
cardiogenic shockacute coronary syndrome (ACS)sepsisAcute Heart Failure (AHF)
Beyond the preview
Go deeper on NL-OMON59337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59337.